HEADER SUGAR BINDING PROTEIN/INHIBITOR 23-JUL-11 3T2T TITLE CRYSTAL STRUCTURE OF HUMAN GALECTIN-1 IN COMPLEX WITH METHYL 2-O- TITLE 2 ACETYL-3-O-TOLUOYL-BETA-D-TALOPYRANOSIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: GALECTIN-1; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: GAL-1, 14 KDA LAMININ-BINDING PROTEIN, HLBP14, 14 KDA COMPND 5 LECTIN, BETA-GALACTOSIDE-BINDING LECTIN L-14-I, GALAPTIN, HBL, HPL, COMPND 6 LACTOSE-BINDING LECTIN 1, LECTIN GALACTOSIDE-BINDING SOLUBLE 1, COMPND 7 PUTATIVE MAPK-ACTIVATING PROTEIN PM12, S-LAC LECTIN 1; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: LGALS1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID KEYWDS BETA SANDWICH, LECTIN, SUGAR BINDING PROTEIN-INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR H.BLANCHARD,P.M.COLLINS REVDAT 4 13-NOV-24 3T2T 1 HETSYN REVDAT 3 29-JUL-20 3T2T 1 REMARK LINK SITE REVDAT 2 03-JUL-13 3T2T 1 JRNL REVDAT 1 28-DEC-11 3T2T 0 JRNL AUTH P.M.COLLINS,C.T.OBERG,H.LEFFLER,U.J.NILSSON,H.BLANCHARD JRNL TITL TALOSIDE INHIBITORS OF GALECTIN-1 AND GALECTIN-3 JRNL REF CHEM.BIOL.DRUG DES. V. 79 339 2012 JRNL REFN ISSN 1747-0277 JRNL PMID 22136701 JRNL DOI 10.1111/J.1747-0285.2011.01283.X REMARK 2 REMARK 2 RESOLUTION. 1.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.5.0109 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 56.14 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 94.9 REMARK 3 NUMBER OF REFLECTIONS : 21603 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.190 REMARK 3 R VALUE (WORKING SET) : 0.188 REMARK 3 FREE R VALUE : 0.226 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1154 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.90 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.95 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1506 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 89.63 REMARK 3 BIN R VALUE (WORKING SET) : 0.2710 REMARK 3 BIN FREE R VALUE SET COUNT : 76 REMARK 3 BIN FREE R VALUE : 0.2970 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2074 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 25 REMARK 3 SOLVENT ATOMS : 134 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 26.44 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.52000 REMARK 3 B22 (A**2) : -1.51000 REMARK 3 B33 (A**2) : 0.00000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.144 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.092 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 7.034 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.935 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.925 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2182 ; 0.012 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 1477 ; 0.001 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 2956 ; 1.383 ; 1.980 REMARK 3 BOND ANGLES OTHERS (DEGREES): 3616 ; 0.770 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 278 ; 6.487 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 106 ;31.965 ;25.283 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 338 ;13.093 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 10 ;18.251 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 317 ; 0.083 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2472 ; 0.006 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): 436 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1350 ; 3.944 ; 4.000 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 548 ; 1.498 ; 4.000 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2162 ; 5.628 ; 6.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 832 ; 4.254 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 788 ; 6.333 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : 1 REMARK 3 REMARK 3 NCS GROUP NUMBER : 1 REMARK 3 CHAIN NAMES : A B REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 1 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 A 1 A 134 4 REMARK 3 1 B 1 B 134 4 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 MEDIUM POSITIONAL 1 A (A): 1681 ; 0.39 ; 0.50 REMARK 3 MEDIUM THERMAL 1 A (A**2): 1681 ; 1.01 ; 2.00 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 1 A 134 REMARK 3 ORIGIN FOR THE GROUP (A): 12.0320 7.5980 12.9640 REMARK 3 T TENSOR REMARK 3 T11: 0.0417 T22: 0.0661 REMARK 3 T33: 0.0344 T12: -0.0089 REMARK 3 T13: -0.0209 T23: 0.0095 REMARK 3 L TENSOR REMARK 3 L11: 0.9064 L22: 2.3655 REMARK 3 L33: 2.2474 L12: -0.0442 REMARK 3 L13: -0.2647 L23: -0.1799 REMARK 3 S TENSOR REMARK 3 S11: 0.1188 S12: -0.0041 S13: 0.0602 REMARK 3 S21: -0.0440 S22: 0.0250 S23: -0.0176 REMARK 3 S31: 0.1929 S32: -0.0739 S33: -0.1437 REMARK 3 REMARK 3 TLS GROUP : 2 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : B 1 B 134 REMARK 3 ORIGIN FOR THE GROUP (A): 10.8730 36.4690 11.4940 REMARK 3 T TENSOR REMARK 3 T11: 0.0005 T22: 0.0696 REMARK 3 T33: 0.0391 T12: 0.0049 REMARK 3 T13: -0.0016 T23: 0.0008 REMARK 3 L TENSOR REMARK 3 L11: 1.4536 L22: 3.5430 REMARK 3 L33: 1.8845 L12: -0.1059 REMARK 3 L13: 0.4667 L23: -0.0825 REMARK 3 S TENSOR REMARK 3 S11: -0.1094 S12: -0.0058 S13: 0.0174 REMARK 3 S21: 0.0580 S22: -0.0114 S23: 0.2478 REMARK 3 S31: -0.0757 S32: -0.0785 S33: 0.1208 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL PARAMETERS FOR MASK CACLULATION REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : NULL REMARK 3 ION PROBE RADIUS : NULL REMARK 3 SHRINKAGE RADIUS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS REMARK 4 REMARK 4 3T2T COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 01-SEP-11. REMARK 100 THE DEPOSITION ID IS D_1000066965. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 16-AUG-09 REMARK 200 TEMPERATURE (KELVIN) : 293 REMARK 200 PH : 6.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : MACSCIENCE REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : OSMIC MIRRORS REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : BRUKER SMART 6000 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : SAINT REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 21603 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.900 REMARK 200 RESOLUTION RANGE LOW (A) : 112.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.6 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.95 REMARK 200 COMPLETENESS FOR SHELL (%) : 91.7 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 49.80 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.45 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.2M AMMONIUM SULPHATE, 25% W/V REMARK 280 POLYETHYLENE GLYCOL 4000, 0.1M SODIUM ACETATE TRIHYDRATE, PH 6.2, REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 22.34350 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 56.14000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.22200 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 56.14000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 22.34350 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 29.22200 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 0 REMARK 465 MET B 0 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OE1 GLU A 74 O HOH A 193 2.12 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 50 90.60 -161.28 REMARK 500 PRO A 78 31.71 -93.52 REMARK 500 ASP A 125 50.76 -96.09 REMARK 500 ASN B 50 83.03 -161.29 REMARK 500 PRO B 78 30.42 -98.84 REMARK 500 ASP B 92 -155.77 -141.22 REMARK 500 ASP B 125 55.70 -91.88 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3TIL RELATED DB: PDB REMARK 900 RELATED ID: 3TIM RELATED DB: PDB DBREF 3T2T A 0 134 UNP P09382 LEG1_HUMAN 1 135 DBREF 3T2T B 0 134 UNP P09382 LEG1_HUMAN 1 135 SEQRES 1 A 135 MET ALA CYS GLY LEU VAL ALA SER ASN LEU ASN LEU LYS SEQRES 2 A 135 PRO GLY GLU CME LEU ARG VAL ARG GLY GLU VAL ALA PRO SEQRES 3 A 135 ASP ALA LYS SER PHE VAL LEU ASN LEU GLY LYS ASP SER SEQRES 4 A 135 ASN ASN LEU CYS LEU HIS PHE ASN PRO ARG PHE ASN ALA SEQRES 5 A 135 HIS GLY ASP ALA ASN THR ILE VAL CYS ASN SER LYS ASP SEQRES 6 A 135 GLY GLY ALA TRP GLY THR GLU GLN ARG GLU ALA VAL PHE SEQRES 7 A 135 PRO PHE GLN PRO GLY SER VAL ALA GLU VAL CME ILE THR SEQRES 8 A 135 PHE ASP GLN ALA ASN LEU THR VAL LYS LEU PRO ASP GLY SEQRES 9 A 135 TYR GLU PHE LYS PHE PRO ASN ARG LEU ASN LEU GLU ALA SEQRES 10 A 135 ILE ASN TYR MET ALA ALA ASP GLY ASP PHE LYS ILE LYS SEQRES 11 A 135 CME VAL ALA PHE ASP SEQRES 1 B 135 MET ALA CYS GLY LEU VAL ALA SER ASN LEU ASN LEU LYS SEQRES 2 B 135 PRO GLY GLU CME LEU ARG VAL ARG GLY GLU VAL ALA PRO SEQRES 3 B 135 ASP ALA LYS SER PHE VAL LEU ASN LEU GLY LYS ASP SER SEQRES 4 B 135 ASN ASN LEU CYS LEU HIS PHE ASN PRO ARG PHE ASN ALA SEQRES 5 B 135 HIS GLY ASP ALA ASN THR ILE VAL CYS ASN SER LYS ASP SEQRES 6 B 135 GLY GLY ALA TRP GLY THR GLU GLN ARG GLU ALA VAL PHE SEQRES 7 B 135 PRO PHE GLN PRO GLY SER VAL ALA GLU VAL CME ILE THR SEQRES 8 B 135 PHE ASP GLN ALA ASN LEU THR VAL LYS LEU PRO ASP GLY SEQRES 9 B 135 TYR GLU PHE LYS PHE PRO ASN ARG LEU ASN LEU GLU ALA SEQRES 10 B 135 ILE ASN TYR MET ALA ALA ASP GLY ASP PHE LYS ILE LYS SEQRES 11 B 135 CME VAL ALA PHE ASP MODRES 3T2T CME A 16 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3T2T CME A 88 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3T2T CME A 130 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3T2T CME B 16 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3T2T CME B 88 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3T2T CME B 130 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE HET CME A 16 10 HET CME A 88 10 HET CME A 130 10 HET CME B 16 10 HET CME B 88 10 HET CME B 130 10 HET MQT A 135 25 HETNAM CME S,S-(2-HYDROXYETHYL)THIOCYSTEINE HETNAM MQT METHYL 2-O-ACETYL-3-O-(4-METHYLBENZOYL)-BETA-D- HETNAM 2 MQT TALOPYRANOSIDE HETSYN MQT METHYL 6-DEOXY-1-SELENO-BETA-L-GALACTOPYRANOSIDE; HETSYN 2 MQT METHYL 2-O-ACETYL-3-O-(4-METHYLBENZOYL)-BETA-D- HETSYN 3 MQT TALOSIDE; METHYL 2-O-ACETYL-3-O-(4-METHYLBENZOYL)-D- HETSYN 4 MQT TALOSIDE; METHYL 2-O-ACETYL-3-O-(4-METHYLBENZOYL)- HETSYN 5 MQT TALOSIDE FORMUL 1 CME 6(C5 H11 N O3 S2) FORMUL 3 MQT C17 H22 O8 FORMUL 4 HOH *134(H2 O) HELIX 1 1 PRO A 101 GLY A 103 5 3 HELIX 2 2 PRO B 101 GLY B 103 5 3 SHEET 1 A12 ALA A 67 TRP A 68 0 SHEET 2 A12 ASP A 54 ASP A 64 -1 N ASP A 64 O ALA A 67 SHEET 3 A12 ASN A 40 ALA A 51 -1 N ARG A 48 O THR A 57 SHEET 4 A12 PHE A 30 ASP A 37 -1 N LEU A 34 O LEU A 43 SHEET 5 A12 ILE A 117 GLY A 124 -1 O ALA A 121 N ASN A 33 SHEET 6 A12 VAL A 5 LEU A 11 -1 N ALA A 6 O MET A 120 SHEET 7 A12 VAL B 5 LEU B 11 -1 O VAL B 5 N SER A 7 SHEET 8 A12 ILE B 117 GLY B 124 -1 O MET B 120 N ALA B 6 SHEET 9 A12 PHE B 30 ASP B 37 -1 N ASN B 33 O ALA B 121 SHEET 10 A12 ASN B 40 ALA B 51 -1 O LEU B 43 N LEU B 34 SHEET 11 A12 ASP B 54 ASP B 64 -1 O ASN B 61 N HIS B 44 SHEET 12 A12 ALA B 67 TRP B 68 -1 O ALA B 67 N ASP B 64 SHEET 1 B12 GLN A 72 GLU A 74 0 SHEET 2 B12 ASP A 54 ASP A 64 -1 N CYS A 60 O GLN A 72 SHEET 3 B12 ASN A 40 ALA A 51 -1 N ARG A 48 O THR A 57 SHEET 4 B12 PHE A 30 ASP A 37 -1 N LEU A 34 O LEU A 43 SHEET 5 B12 ILE A 117 GLY A 124 -1 O ALA A 121 N ASN A 33 SHEET 6 B12 VAL A 5 LEU A 11 -1 N ALA A 6 O MET A 120 SHEET 7 B12 VAL B 5 LEU B 11 -1 O VAL B 5 N SER A 7 SHEET 8 B12 ILE B 117 GLY B 124 -1 O MET B 120 N ALA B 6 SHEET 9 B12 PHE B 30 ASP B 37 -1 N ASN B 33 O ALA B 121 SHEET 10 B12 ASN B 40 ALA B 51 -1 O LEU B 43 N LEU B 34 SHEET 11 B12 ASP B 54 ASP B 64 -1 O ASN B 61 N HIS B 44 SHEET 12 B12 GLN B 72 ARG B 73 -1 O GLN B 72 N CYS B 60 SHEET 1 C10 GLU A 105 PRO A 109 0 SHEET 2 C10 ASN A 95 LYS A 99 -1 N LEU A 96 O PHE A 108 SHEET 3 C10 SER A 83 PHE A 91 -1 N CME A 88 O LYS A 99 SHEET 4 C10 CME A 16 VAL A 23 -1 N VAL A 23 O SER A 83 SHEET 5 C10 PHE A 126 ASP A 134 -1 O LYS A 129 N ARG A 20 SHEET 6 C10 PHE B 126 ASP B 134 -1 O VAL B 131 N VAL A 131 SHEET 7 C10 CME B 16 VAL B 23 -1 N CME B 16 O ASP B 134 SHEET 8 C10 VAL B 84 PHE B 91 -1 O VAL B 87 N VAL B 19 SHEET 9 C10 ASN B 95 LYS B 99 -1 O LYS B 99 N CME B 88 SHEET 10 C10 GLU B 105 PRO B 109 -1 O PHE B 108 N LEU B 96 LINK C GLU A 15 N CME A 16 1555 1555 1.32 LINK C CME A 16 N LEU A 17 1555 1555 1.33 LINK C VAL A 87 N CME A 88 1555 1555 1.34 LINK C CME A 88 N ILE A 89 1555 1555 1.33 LINK C LYS A 129 N CME A 130 1555 1555 1.34 LINK C CME A 130 N VAL A 131 1555 1555 1.32 LINK C GLU B 15 N CME B 16 1555 1555 1.33 LINK C CME B 16 N LEU B 17 1555 1555 1.34 LINK C VAL B 87 N CME B 88 1555 1555 1.33 LINK C CME B 88 N ILE B 89 1555 1555 1.32 LINK C LYS B 129 N CME B 130 1555 1555 1.32 LINK C CME B 130 N VAL B 131 1555 1555 1.33 CRYST1 44.687 58.444 112.280 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.022378 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017110 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008906 0.00000